R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012.
DOI : 10.3322/caac.20138

P. Friedl and A. S. , Cancer Invasion and the Microenvironment: Plasticity and Reciprocity, Cell, vol.147, issue.5, pp.992-1009, 2012.
DOI : 10.1016/j.cell.2011.11.016

R. Carretero, E. Wang, A. Rodriguez, J. Reinboth, M. Ascierto et al., Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes, International Journal of Cancer, vol.129, issue.2, 2011.
DOI : 10.1002/ijc.26471

R. Schreiber, L. Old, and M. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-1570, 2011.
DOI : 10.1126/science.1203486

J. Galon, F. Pages, F. Marincola, M. Thurin, G. Trinchieri et al., The immune score as a new possible approach for the classification of cancer, Journal of Translational Medicine, vol.10, issue.1, pp.1-4, 2012.
DOI : 10.1186/1479-5876-9-32

URL : https://hal.archives-ouvertes.fr/inserm-00664981

S. Topalian, G. Weiner, and D. Pardoll, Cancer Immunotherapy Comes of Age, Journal of Clinical Oncology, vol.29, issue.36, pp.4828-4836, 2011.
DOI : 10.1200/JCO.2011.38.0899

J. Galon, L. Emens, S. Silverstein, S. Klief, and F. Marincola, organizers: Focus on the Target: The Tumor Microenvironment

A. Kuraishy, M. Karin, and S. Grivennikov, Tumor Promotion via Injury- and Death-Induced Inflammation, Immunity, vol.35, issue.4, pp.467-477, 2011.
DOI : 10.1016/j.immuni.2011.09.006

J. Condeelis and J. Pollard, Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis, Cell, vol.124, issue.2, pp.263-266, 2006.
DOI : 10.1016/j.cell.2006.01.007

S. Budhu, J. Loike, A. Pandolfi, S. Han, G. Catalano et al., T cell concentration determines their efficiency in killing cognate antigen???expressing syngeneic mammalian cells in vitro and in mouse tissues, The Journal of Experimental Medicine, vol.46, issue.1, pp.223-235, 2010.
DOI : 10.1016/0022-1759(86)90079-7

F. Pages, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005.
DOI : 10.1056/NEJMoa051424

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Miecnik et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.
DOI : 10.1126/science.1129139

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea et al., Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, Journal of Clinical Oncology, vol.29, issue.6, pp.610-618, 2011.
DOI : 10.1200/JCO.2010.30.5425

S. Ladoire, G. Mignot, S. Dabakuyo, L. Arnould, L. Apetoh et al., In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, The Journal of Pathology, vol.5, issue.3, pp.389-400, 2011.
DOI : 10.1002/path.2866

K. Shimizu, M. Nakata, Y. Hirami, T. Yukawa, A. Maeda et al., Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.5, issue.5, pp.585-590, 2010.
DOI : 10.1097/JTO.0b013e3181d60fd7

S. Ladoire, F. Martin, and F. Ghiringhelli, Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer, Cancer Immunology, Immunotherapy, vol.112, issue.7, pp.909-918, 2011.
DOI : 10.1007/s00262-011-1046-y

T. Gajewski, J. Louahed, and V. Brichard, Gene Signature in Melanoma Associated With Clinical Activity, The Cancer Journal, vol.16, issue.4, pp.399-403, 2010.
DOI : 10.1097/PPO.0b013e3181eacbd8

E. Wang, L. Miller, G. Ohnmacht, S. Mocellin, A. Perez-diaz et al., Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness, Cancer Res, vol.62, pp.3581-3586, 2001.

M. Ascierto, D. Giorgi, V. Liu, Q. Bedognetti, D. Spivey et al., An immunologic portrait of cancer, Journal of Translational Medicine, vol.9, issue.1, p.146, 2011.
DOI : 10.1158/1078-0432.CCR-08-3323

L. Apetoh, . Ghiringhelli-jf, A. Tesniere, M. Obeid, C. Ortiz et al., Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007.
DOI : 10.1038/nm1622

URL : https://hal.archives-ouvertes.fr/hal-00316924

S. Demaria, M. Volm, R. Shapiro, H. Yee, R. Oratz et al., Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin Cancer Res, vol.7, pp.3025-3030, 2001.

C. Taylor, D. Hershman, N. Shah, N. Suciu-foca, D. Petrylak et al., Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy, Clinical Cancer Research, vol.13, issue.17, pp.5133-5143, 2007.
DOI : 10.1158/1078-0432.CCR-07-0507

. Emens, http://www.translational-medicine.com/content, Journal of Translational Medicine, vol.1010, issue.1, p.7070, 2012.

S. Ladoire, L. Arnould, G. Mignot, L. Apetoh, R. C. Martin et al., T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival, British Journal of Cancer, vol.23, issue.3, pp.366-371, 2011.
DOI : 10.1038/nri1936

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger et al., Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research, vol.71, issue.4, pp.1263-1271, 2011.
DOI : 10.1158/0008-5472.CAN-10-2907

J. Loike, L. Cao, S. Budhu, S. Hoffman, and S. Silverstein, Blockade of ??5??1 Integrins Reverses the Inhibitory Effect of Tenascin on Chemotaxis of Human Monocytes and Polymorphonuclear Leukocytes Through Three-Dimensional Gels of Extracellular Matrix Proteins, The Journal of Immunology, vol.166, issue.12, pp.7534-7542, 2001.
DOI : 10.4049/jimmunol.166.12.7534

E. Broussard and M. Disis, TNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory, Journal of Clinical Oncology, vol.29, issue.6, pp.601-603, 2011.
DOI : 10.1200/JCO.2010.32.9078

J. Mcalpine, H. Porter, M. Kobel, B. Nelson, L. Prentice et al., BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma, Modern Pathology, vol.451, issue.5, p.1
DOI : 10.1038/modpathol.2011.211

G. Gorgun and K. Anderson, Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer, pp.1253-1264, 2011.

T. Donnem, K. Shibli, S. Andersen, S. Saad, K. Busund et al., Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer, Cancer, vol.18, issue.suppl 1, pp.4318-4325, 2010.
DOI : 10.1002/cncr.25333

R. Ferris, E. Jaffee, and S. Ferrone, Tumor Antigen???Targeted, Monoclonal Antibody???Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape, Journal of Clinical Oncology, vol.28, issue.28, pp.4390-4399, 2010.
DOI : 10.1200/JCO.2009.27.6360

L. Emens, Driving effective tumor immunity with combinatorial immunotherapy, American Society of Clinical Oncology 2010 Educational Book. Edited by: Govindan R, pp.460-465

P. Kim, T. Armstrong, H. Song, M. Wolpoe, V. Weiss et al., Antibody association with HER-2/neu???targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs, Journal of Clinical Investigation, vol.118, issue.5, pp.1700-1711, 2008.
DOI : 10.1172/JCI34333

D. Gabrilovich, T. Ishida, S. Nadaf, J. Ohm, and D. Carbone, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, vol.5, pp.2963-2970, 1999.

J. Ozao-choy, G. Ma, J. Kao, G. Wang, M. Meseck et al., The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies, Cancer Research, vol.69, issue.6, pp.2514-2522, 2009.
DOI : 10.1158/0008-5472.CAN-08-4709

J. Ko, A. Zea, B. Rini, J. Ireland, P. Elson et al., Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.15, issue.6, pp.2148-2157, 2009.
DOI : 10.1158/1078-0432.CCR-08-1332

E. Manning, J. Ullman, J. Leatherman, J. Asquith, T. Hansen et al., A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism, Clinical Cancer Research, vol.13, issue.13, pp.3951-3959, 2007.
DOI : 10.1158/1078-0432.CCR-07-0374

B. Castella, C. Riganti, F. Fiore, F. Pantaleoni, M. Canepari et al., Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V??9V??2 T Cells, ???? CD8+ T Cells, Regulatory T Cells, and Dendritic Cells, The Journal of Immunology, vol.187, issue.4, pp.1578-1590, 2011.
DOI : 10.4049/jimmunol.1002514

T. Rogers and I. Holen, Tumour macrophages as potential targets of bisphosphonates, Journal of Translational Medicine, vol.9, issue.1, pp.177-180, 2011.
DOI : 10.1023/A:1013026313647

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.
DOI : 10.1056/NEJMoa1003466

B. Rini, V. Weinberg, L. Fong, S. Conry, R. Hershberg et al., Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy, Cancer, vol.101, issue.1, pp.67-74, 2006.
DOI : 10.1002/cncr.21956

M. Disis, D. Wallace, T. Gooley, Y. Dang, M. Slota et al., -Specific Vaccination in Patients With Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.28, pp.4685-4692, 2009.
DOI : 10.1200/JCO.2008.20.6789

URL : https://hal.archives-ouvertes.fr/inserm-00691923

L. Emens, R. Gupta, S. Petrik, M. Laiko, J. Levi et al., A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.2535, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.2535

L. Liau, R. Prins, S. Kiertscher, S. Odesa, T. Kremen et al., Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment, Clinical Cancer Research, vol.11, issue.15, pp.5515-5525, 2005.
DOI : 10.1158/1078-0432.CCR-05-0464

J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus et al., Phase I Study of Single-Agent Anti???Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-3175, 2010.
DOI : 10.1200/JCO.2009.26.7609

S. Jensen, L. Maston, M. Gough, C. Ruby, W. Redmond et al., Signaling Through OX40 Enhances Antitumor Immunity, Seminars in Oncology, vol.37, issue.5, pp.524-532, 2010.
DOI : 10.1053/j.seminoncol.2010.09.013

G. Beatty, E. Chiorean, M. Fishman, B. Saboury, U. Teifelbaum et al., CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, vol.331, issue.6024, pp.401612-1616, 2011.
DOI : 10.1126/science.1198443

J. Dubovsky, A. Villagra, J. Powers, H. Wang, J. Pinilla-ibarz et al., Circumventing Immune Tolerance Through Epigenetic Modification, Current Pharmaceutical Design, vol.16, issue.3, pp.268-276, 2010.
DOI : 10.2174/138161210790170120